← Back to Event List

PhD Proposal Defense: Michael Zhang

Location

The Commons : 331

Date & Time

July 10, 2019, 10:00 am12:00 pm

Description

Wednesday, July 10th at 10:00 a.m.
Commons Room 331
Light refreshments will be provided.

Engineering B Cell-Carrying Vaccines for Enhancing T-Cell Cancer Immunotherapy

Antigen presenting cells (APCs) have been extensively developed for therapeutic cancer vaccine use. The most potent APCs in the immune system in activating T-cell immunity are dendritic cells (DCs). Therapeutic vaccine strategies utilize DCs by ex vivo DC reprogramming with delivered antigen and adjuvant, mounting a durable anti-cancer T-cell response upon reinfusion to patients. However, DCs are not ideal APC candidates for ex vivo reprogramming and large-scale clinical vaccine use, highlighted by their low abundance in peripheral blood for clinical access, complex conditioning and adjuvant regimens for maintaining differentiation, and relatively poor proliferation potential.

 

B cells are an alternative source of APCs for therapeutic cancer vaccines due to their relative abundance in the peripheral blood and relatively high proliferation potential compared to DCs. The natural biology of B cells enables antigen-specific B-cell uptake and presentation to CD4+ T cells, but not efficient non-specific uptake and presentation to naïve CD8+ T cells, hindering translation of B-cell carriers for therapeutic cancer vaccines. I propose lipid-conjugation of antigens and adjuvants will provide a modular delivery system that can induce B cells to carry lipid-tailed cargo for enhanced priming of CD4+ and CD8T cells. My proposed aims are 1) to synthesize and deliver lipid-conjugated antigens to B cells for increased presentation, 2) to deliver lipid coupled adjuvants to B cells for enhanced adjuvant efficacy, and 3) to prime CD4and CD8T cells with loaded B-cell carriers for enhanced anti-tumor immunity. The use of lipid-conjugation to facilitate delivery to B cells will allow for a modular platform of delivering antigen and adjuvant combinations that are best suited for inducing T-cell immunity and reveal underappreciated B-cell biology that can be exploited for therapeutic B-cell carrying vaccines in cancer and other chronic diseases.